Skip to main content
main-content

16-06-2017 | Androgen deprivation therapy | Video

STAMPEDE trial changes standard of care

Nicholas James discusses the STAMPEDE trial results supporting the upfront use of abiraterone in advanced prostate cancer patients beginning long-term androgen deprivation therapy.